908 Devices and CPI Improve mAbs Cell Culture Outcomes Using At-line Media Analysis

Rhea-AI Summary

908 Devices (NASDAQ: MASS) announced a successful collaboration with CPI, demonstrating their REBEL™ device's ability to enhance cell growth in bioprocessing. Using the REBEL, CPI optimized nutrient levels for a monoclonal antibody-producing cell line, achieving up to a 40% increase in titer while controlling toxic metabolite accumulation. The REBEL provides real-time data tracking, facilitating informed decisions on feeding strategies and improving both efficiency and product quality.

Positive

• Achieved up to a 40% increase in titer while maintaining low toxic metabolite levels.
• Real-time data tracking enhances decision-making in bioprocessing.
• Integration with Umetrics® data software facilitates effective data analysis.

Negative

• None.

REBEL mass spec device used to reduce toxic metabolite accumulation while increasing cell viability and titer by up to 40%

BOSTON--(BUSINESS WIRE)-- 908 Devices (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, announced that its collaboration with CPI is demonstrating the value of at-line cell culture media analysis to inform feeding strategies for improved cell growth in bioprocessing applications. Using data from 908 Devices’ REBEL™ desktop device, CPI process engineers optimized nutrients of a monoclonal antibody-expressing cell line to increase titer and control toxic metabolites.

CPI process engineers used the REBEL device to monitor amino acid depletion across a panel of eight commercial cell culture media at high and low glucose concentrations in a 14-day fed-batch process in Ambr® 15 micro-bioreactors. Time course data from the REBEL provided unique insights into the cell metabolism, in addition to typical cell culture parameters. In a second run using the Ambr 15 system, these real-time data sets enabled refinement of media feeding strategies to correct amino acid depletion, improve cell viability and reduce toxic metabolite accumulation. Results of the tailored feeding approach, which used a low feed concentration and amino acid supplementation, enabled up to a 40% increase in titer while maintaining low levels of toxic metabolites.

The wealth of data provided by the REBEL along with multivariate modeling and statistical analysis enables users to make such informed decisions about their process as well as develop predictive models for feed control, leading to improved efficiency and robust product quality.

The REBEL analyzer integrates with the well-known and broadly used Umetrics® data software suite from Sartorius. Data from the REBEL can be seamlessly imported into MODDE® for design of experiments (DoE) and SIMCA® for rapid data visualization and multivariate trend tracking. CPI used SIMCA and MODDE to perform multivariate analysis of the REBEL data to expedite the identification of optimal feeding conditions.

CPI is an independent UK-based innovation organization that works with companies to develop, prove, scale up, and commercialize new products and processes. To learn more, view the webinar: Harness the Power of At-line Spent Media Analysis Using the REBEL to Optimize a CHO mAb Fed-Batch Process.

About the REBEL analyzer

REBEL is a first-of-its-kind fresh and spent media analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line. Key benefits include:

• Efficiency – minimal sample preparation and tiny volume requirements
• Real-time data tracking – quantitate over 30 key media nutrients in <10 minutes
• Small and simple – versatile design valued by users across many applications

For more information, visit www.908devices.com.

Ambr, Umetrics, MODDE and SIMCA are registered trademarks of Sartorius AG. REBEL is a trademark of 908 Devices Inc.

About 908 Devices

908 Devices Inc. (Nasdaq: MASS) is democratizing laboratory mass spectrometry with its simple handheld and desktop devices, addressing critical-to-life applications. The Company’s devices are used at the point-of-need to interrogate unknown and invisible materials and provide quick, actionable answers to directly address some of the most critical problems in life sciences research, bioprocessing, pharma / biopharma, forensics and adjacent markets. The Company is headquartered in the heart of Boston, where it designs and manufactures innovative products that bring together the power of mass spectrometry, microfluidic separations, software automation and machine learning.

Forward Looking Statements

This press release includes “forward looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the expected uses and capabilities of the Company’s products. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on management’s current expectations and involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including the risks outlined under “Risk Factors” and elsewhere in the Company’s filings with the Securities and Exchange Commission which are available on the SEC's website at www.sec.gov. Additional information will be made available in the Company’s annual and quarterly reports and other filings that it makes from time to time with the SEC. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221012006003/en/

Media

Barbara Russo

brusso@908devices.com

Investor

Carrie Mendivil

IR@908devices.com

Source: 908 Devices Inc.

FAQ

What is the significance of the REBEL device for 908 Devices (MASS)?

The REBEL device is crucial for improving cell growth and titer in bioprocessing, showcasing its effectiveness in optimizing feeding strategies.

How much increase in titer was achieved using the REBEL device?

The REBEL device enabled up to a 40% increase in titer during the optimization process.

What collaboration did 908 Devices (MASS) recently announce?

908 Devices announced a collaboration with CPI to demonstrate the effectiveness of their REBEL device in bioprocessing applications.

How does the REBEL device benefit biopharma researchers?

The REBEL device provides real-time data tracking for over 30 key media nutrients, aiding in process development and maximizing bioreactor utilization.